82 related articles for article (PubMed ID: 6858770)
1. The effects of pergolide on the cardiovascular system of 40 patients with Parkinson's disease.
Leibowitz M; Lieberman AN; Neophytides A; Gopinathan G; Goldstein M
Adv Neurol; 1983; 37():121-30. PubMed ID: 6858770
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M
Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782
[TBL] [Abstract][Full Text] [Related]
3. Cardiac effects of pergolide.
Leibowitz M; Lieberman A; Goldstein M; Neophytides A; Kupersmith M; Gopinathan G; Mehl S
Clin Pharmacol Ther; 1981 Dec; 30(6):718-23. PubMed ID: 7307421
[TBL] [Abstract][Full Text] [Related]
4. Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both.
Ozer F; Tiras R; Cetin S; Ozturk O; Aydemir T; Ozben S; Meral H; Kizkin S; Bader H; Ozben B
J Clin Neurosci; 2009 Jan; 16(1):83-7. PubMed ID: 19014887
[TBL] [Abstract][Full Text] [Related]
5. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
6. Pergolide and lisuride in advanced Parkinson's disease.
Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
[TBL] [Abstract][Full Text] [Related]
7. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
[TBL] [Abstract][Full Text] [Related]
8. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.
Kulisevsky J; López-Villegas D; García-Sánchez C; Barbanoj M; Gironell A; Pascual-Sedano B
Clin Neuropharmacol; 1998; 21(6):358-62. PubMed ID: 9844794
[TBL] [Abstract][Full Text] [Related]
9. An open label trial of pergolide in Thai patients with Parkinson's disease.
Poungvarin N; Prayoonwiwat N; Devahasatin V; Viriyavejakul A
J Med Assoc Thai; 1996 Apr; 79(4):205-9. PubMed ID: 8708504
[TBL] [Abstract][Full Text] [Related]
10. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
[TBL] [Abstract][Full Text] [Related]
11. [Pergolide mesylate in the treatment of Parkinson's disease resistant to other treatments. First Italian experience].
Pezzoli G; Zecchinelli A; Mariani C; Reganati P; Scarlato G
Clin Ter; 1991 Jan; 136(1):39-45. PubMed ID: 1826872
[TBL] [Abstract][Full Text] [Related]
12. Trial of subtherapeutic pergolide in de novo Parkinson's disease.
Grosset K; Grosset D; Lees A;
Mov Disord; 2005 Mar; 20(3):363-6. PubMed ID: 15580607
[TBL] [Abstract][Full Text] [Related]
13. Pergolide in late-stage Parkinson disease.
Lang AE; Quinn N; Brincat S; Marsden CD; Parkes JD
Ann Neurol; 1982 Sep; 12(3):243-7. PubMed ID: 6753730
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
[TBL] [Abstract][Full Text] [Related]
15. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
[TBL] [Abstract][Full Text] [Related]
16. Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease.
Tanner CM; Chhablani R; Goetz CG; Klawans HL
Neurology; 1985 Jun; 35(6):918-21. PubMed ID: 3889707
[TBL] [Abstract][Full Text] [Related]
17. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
[TBL] [Abstract][Full Text] [Related]
18. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
Kim JY; Chung EJ; Park SW; Lee WY
Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
[TBL] [Abstract][Full Text] [Related]
19. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
van Strater AC; Bax JJ; van Hilten JJ; Jukema JW
Ned Tijdschr Geneeskd; 2005 Apr; 149(16):891-4. PubMed ID: 15868996
[TBL] [Abstract][Full Text] [Related]
20. Effects of pergolide on nocturia in Parkinson's disease: three female cases selected from over 400 patients.
Kuno S; Mizuta E; Yamasaki S; Araki I
Parkinsonism Relat Disord; 2004 Mar; 10(3):181-7. PubMed ID: 15036175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
